Related Experiment Video
Updated: Jun 13, 2026
04:15
A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
Selectin inhibitors: a patent review
Patricia W Bedard1, Neelu Kaila
1Pfizer, BioTherapeutics, Biocorrections Research Unit, 200 CambridgePark Drive, Cambridge, MA 02140, USA. pbedard@wyeth.com
Expert Opinion on Therapeutic Patents
|April 23, 2010
Summary
Selectin inhibition has advanced, with new patents and clinical trials demonstrating effective disease modification. This review covers developments in selectin-targeted therapeutics from 2003 to 2009.
Area of Science:
- Immunology and molecular biology
- Drug discovery and development
Background:
- Selectins are key mediators of leukocyte adhesion in inflammation and immune responses.
- Dysregulation of selectins contributes to diseases like atherosclerosis and tumor metastasis.
- Selectin blockade offers a therapeutic strategy for various pathologies.
Purpose of the Study:
- To review patents and patent applications concerning selectin inhibition published since 2003.
- To assess advancements in the clinical safety and efficacy of selectin-targeting therapeutics.
- To provide a comprehensive overview of developments in selectin inhibition.
Main Methods:
- Review of patents and patent applications filed between 2003 and August 2009.
- Analysis of available clinical trial data for selectin inhibitors.
- Inclusion of relevant scientific literature.
Main Results:
- Significant progress in developing drug-like molecules to inhibit selectin/ligand interactions.
- Demonstrated ability of selectin inhibitors to modify disease pathology in human trials.
- Overview of new patents and therapeutic developments in selectin inhibition.
Conclusions:
- The field of selectin inhibition has matured considerably.
- Therapeutic strategies targeting selectins show promise for disease amelioration.
- Inhibiting selectin-ligand interactions is a viable approach for treating inflammatory and metastatic diseases.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Selectins
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain, which...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.